Introduction
============

Although women tend to have a lower prevalence of obstructive coronary artery disease (CAD), previous evidence indicated that women experience relatively worse outcomes compared with men among patients presenting with stable chest pain [@R1]--[@R3]. Of multiple potential explanations for this difference, variation by sex in the decision-making of diagnostic strategy may emerge as a particularly strong candidate [@R4],[@R5]. Recently, data from the PROMISE trial have suggested that influences of sex on the entire diagnostic pathway highlighted the need for sex-specific approaches to the evaluation and diagnosis of obstructive CAD [@R6].

Current guidelines for the evaluation of patients presenting with stable chest pain dictate further diagnostic strategy on the basis of the pretest probability (PTP) of obstructive CAD [@R7]--[@R10]. Although the Updated Diamond--Forrester method (UDFM) [@R11] and the Duke clinical score (DCS) [@R12] are the most validated and recommended models, quite a few observations have suggested that both models overestimated the actual prevalence of obstructive CAD, especially in populations with low prevalence [@R13]--[@R17]. However, few studies have systematically examined the impact of sex-related differences on the assessment of PTP by UDFM or DCS.

Thus, we recruited a coronary computed tomography angiography (CCTA)-based cohort to validate and compare the relative accuracy for estimating PTP of obstructive CAD by UDFM and DCS in symptomatic men and women, respectively.

Patients and methods
====================

Study population
----------------

This study included consecutive patients who presented with stable chest pain and were referred for CCTA in our institution from October 2015 to September 2017. Patients were excluded if they fulfilled one of the following criteria: acute coronary syndrome, previous CAD or coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting), impaired renal function (serum creatinine\>120 μmol/l), New York Heart Association class III or IV heart failure, atrial fibrillation, aortic disease, age more than 90 years, or patients with unassessable segments because of artifact. This retrospective and observational study was approved by the ethics committee of our institution.

Data collection and definitions
-------------------------------

The following variables were registered: sex, age, BMI, hypertension, hyperlipidemia, diabetes, smoking, changes in resting ECG, and family history of premature CAD. Chest pain symptoms were categorized as nonanginal chest pain, atypical angina, or typical angina as described previously by Diamond [@R18]. Hypertension was defined as blood pressure of at least 140/90 mmHg or the use of anti-hypertension medication. Hyperlipidemia was defined as total cholesterol of at least 220 mg/dl, low-density lipoprotein cholesterol of at least 140 mg/dl, fasting triglycerides of at least 150 mm/dl, or receiving treatment with oral lipid-lowering agents. Diabetes was defined as fasting glucose levels over 7 mmol/l or treatment currently with either diet, oral glucose-lowering agents, or insulin. Smoking was defined as current smoking or smoking in the past 6 months. A family history of premature coronary heart disease was defined as myocardial infarction (MI) occurring before the age of 50 years in a first-degree male relative or before the age of 55 years in a first-degree female relative. Changes in the resting ECG were defined as at least 1 mm depression in at least two adjacent leads. The PTP of obstructive CAD was calculated using UDFM [@R11] and DCS [@R12],[@R19], respectively.

Coronary computed tomographic angiography
-----------------------------------------

All scans were performed using a second-generation dual-source CCTA scanner (Somatom Definition Flash; Siemens Medical Solutions, Forchheim, Germany). Sublingual nitroglycerine and heart-rate control for a target heart rate of at least 70 beats/min were administered as appropriate. Afterwards, a contrast-enhanced CCTA was performed with detector collimation of 2×128×0.6 mm, a slice thickness of 0.6 mm, gantry rotation time of 280 ms, heart rate adaptive pitch of 0.2--0.5, tube current of 290--560 mAs/rotation, and tube voltage of 80--120 kV. Contrast volume was 60--90 ml (Ultravist, 370 mgI/ml; Schering AG, Guangzhou, China), followed by a normal saline of 50 ml, and was injected intravenously into an antecubital vein at 5 ml/s. Bolus tracking is used to synchronize the arrival of contrast in the coronary arteries and the initiation of the scan, and the region of interest was set at the root of the ascending aorta. Data acquisition was initiated with a delay of 5 s after the signal attenuation threshold (100 HU) was reached in region of interest. Image scan was triggered from 30 to 80% of the R--R interval.

Three experienced observers, who were blinded to the clinical data, evaluated the CCTA data on a Syngo Multimodality workstation (Siemens, Munich, Germany). Interobserver disagreements were resolved by consensus. In image analyses, all segments at least 2 mm in diameter were identified and analyzed using the CAD-RADS Coronary Artery Disease -- Reporting and Data System [@R20]. Obstructive CAD was defined as present if a patient had at least one lesion with at least 50% diameter stenosis.

Follow-up
---------

Follow-up information was obtained by a phone call and/or a physician visit after CCTA. The major adverse cardiovascular event (MACE) was composed of cardiac death, nonfatal MI, unstable angina hospitalization, and late revascularization. Cardiac death was defined as any death caused by cardiac disease or for which no other cause could be found. MI was defined when at least two of the following three criteria were fulfilled: chest pain or equivalent symptom complex, positive cardiac biomarkers, or typical ECG changes [@R21]. Late revascularizations (\>60 days after CCTA) are more likely to be associated with CAD progression.

Statistical analysis
--------------------

Continuous variables were compared using Student's *t*-tests or Mann--Whitney *U*-tests as appropriate and were expressed as mean±SD. Count variables were expressed as frequencies with percentages and differences in the percentages were assessed using the *χ*^2^-test or Fisher's exact test as appropriate. To compare the predictive value of UDFM and DCS in men and women, the present study used distinct approaches. First, the improvement in discrimination was quantified using the area under receiver-operator characteristic curve (AUC) [@R22] and the integrated discrimination improvement (IDI) [@R23]. Second, we evaluated whether both models correctly classified patients into different categories of PTP. Using the PTP categories less than 15, 15--85, and more than 85% [@R8],[@R9], the net reclassification improvement (NRI) [@R23] was assessed. Third, Hosmer--Lemeshow (H-L) tests divided patients into ten groups according to deciles of PTP, each of which was represented by a dot on the calibration plot and an overall *χ*^2^ statistic was calculated separately for men and women [@R24]. All statistical analyses were carried out by MedCalc (version 15.2.2; MedCalc Software, Mariakerke, Belgium) and SAS (version 9.2; SAS Institute Inc., Cary, North Carolina, USA). Two-tailed *P* value less than 0.05 was considered statistically significant.

Results
=======

Sex-specific means or corresponding percentages of baseline variables are described in Table [1](#T1){ref-type="table"}. The study cohort included 5777 patients, of whom 1882 (33%) were found to have obstructive CAD on CCTA. The mean ages were 55 years for men and 59 years for women. Women were more likely than men to have low BMI, hypertension, hyperlipidemia, and a family history of premature CAD. The prevalence of diabetes and changes in resting ECG were similar in men and women. Compared with women, men were more likely to smoke and have obstructive CAD on CCTA. The most common symptom in both sexes was atypical angina, which was reported by 46% of women versus 41% of men.

###### 

Patient characteristics and pretest probability

![](mca-30-124-g001)

Comparison of discrimination using AUC and IDI is shown in Table [2](#T2){ref-type="table"}. An evaluation of AUC showed little difference between the performance of UDFM and DCS in men (0.782 vs. 0.785, *P*=0.4708) and women (0.668 vs. 0.654, *P*=0.1255), respectively. By contrast, the IDI for UDFM was negative compared with DCS in men (−12%, *P*\<0.0001) and women (−8%, *P*\<0.0001), respectively.

###### 

Differentiation of updated Diamond--Forrester method and Duke clinical score in men and women
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To assess calibration, predicted probabilities of obstructive CAD were compared with observed probabilities detected on CCTA in deciles of predicted probabilities (Fig. [1](#F1){ref-type="fig"}). The differences between observed and predicted probabilities were evident in H-L calibration plots: UDFM manifested a predominance of overestimation in men, but underestimation in women, and DCS overestimated the prevalence of obstructive CAD in both men and women. Statistically, no calibration was acceptable (UDFM in men: H-L *χ*^2^=153.97, *P*\<0.01; DCS in men: H-L *χ*^2^=110.44, *P*\<0.01; UDFM in women: H-L *χ*^2^=174.98, *P*\<0.01; DCS in women: H-L *χ*^2^=140.37, *P*\<0.01).

![Predicted and observed proportions in men and women, by deciles of PTP. Hosmer--Lemeshow *χ*^2^ statistic: UDFM in men: 153.97, *P*\<0.01; DCS in men: 110.44, *P*\<0.01; UDFM in women: 174.98, *P*\<0.01; DCS in women: 140.37, *P*\<0.01. DCS, Duke clinical score; PTP, pretest probability; UDFM, updated Diamond--Forrester method.](mca-30-124-g003){#F1}

Table [3](#T3){ref-type="table"} shows the classification of women on the basis of UDFM and DCS into categories of PTP (\<15, 15--85, and \>85%). Of the 2078 negative women, by DCS, 471 were reclassified correctly to a lower PTP category, but 40 were classified to a higher PTP category. Of the 698 positive men, 126 were reclassified correctly to a higher PTP category, but 81 were classified to a lower PTP category. Thus, compared with UDFM, the NRI for DCS was 20.75% for negative, 6.45% for positive, and 27.20% overall (*P*\<0.0001). The results were different when the analysis was carried out on men (Table [4](#T4){ref-type="table"}). The NRI was as follows: 1.76% for negative, 15.04% for positive, and 16.80% overall (*P*\<0.0001).

###### 

Reclassification table using pretest probability categories less than 15, 15--85, and more than 85% (women)
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###### 

Reclassification table using pretest probability categories less than 15, 15--85, and more than 85% (men)
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During a median follow-up of 13 months (interquartile range: 6--20 months), 203 (3.5%) patients were lost to follow-up. MACEs occurred in 249 (4.3%) patients, including 11 (0.2%) cardiovascular deaths, 28 (0.5%) nonfatal MIs, 93 (1.6%) unstable angina hospitalization, and 117 (2.0%) late revascularizations.

UDFM classified more than half (1188/2078) the negative women into the medium PTP group, for which noninvasive testing was recommend according to the current guidelines. However, among the 1188 negative women, only 31 MACEs occurred (2.6%, one cardiovascular death, three nonfatal MIs, eight unstable anginas, and 19 late revascularizations). Use of DCS instead of UDFM would imply a change of diagnostic strategy in these negative women: 40% (471/1188) into the low PTP group, for which no further test was recommend. Moreover, among the 471 negative women, only seven MACEs occurred (1.5%, no cardiovascular death, one nonfatal MI, one unstable angina, and five late revascularizations).

Discussion
==========

In this CCTA-based analysis of patients with symptoms suggestive of stable CAD, we observed substantial sex-based differences in the clinical presentation and diagnostic evaluation. Although DCS seemed to perform better than UDFM with a positive NRI and IDI, neither of them showed a favorable AUC and calibration in women. Moreover, use of DCS instead of UDFM would alter the diagnostic strategy in women, resulting in a decrease in unnecessary testing. To our knowledge, this is the first comparative description of the sex-based differences in the calculation of PTP by the most proposed models, UDFM and DCS.

Consistent with our study, data from the PROMISE trial found that although women were more likely to be characterized as having a low PTP, they had larger traditional risk factor burden than men, except for BMI, diabetes, and smoking [@R6]. Furthermore, previous investigations have suggested that the most common symptom type was atypical angina and women are more likely to present with atypical angina than men [@R6],[@R25], which were similar to that noted in the present analysis. Thus, selection of optimal PTP models to ensure that they sufficiently account for the discrepancy between the higher prevalence of traditional risk factors and the lower reported prevalence of obstructive CAD is crucial in the development of a diagnostic strategy for women presenting with stable chest pain [@R5],[@R6].

A number of previous studies have indicated that either UDFM or DCS overestimated the actual prevalence of obstructive CAD, especially in populations with low prevalence [@R13]--[@R17], which was confirmed by the unsatisfactory calibration in the current analysis, especially for women. By UDFM, more than half women were classified into the low PTP group, resulting in a marked underestimation manifested in the H-L calibration plots. Moreover, in women, the AUCs for both models were moderate (0.668 for UDFM and 0.654 for DCS), which was in line with a recently published study [@R26], yielding an AUC of 0.61 for UDFM and 0.59 for DCS in women referred to CCTA.

We noted two potential reasons for the unsatisfactory performance when applying the traditional age, sex, and chest pain typicality-based approach for women. First, the PTP models might show divergent predictions across patients differing only by sex [@R4]. For example, according to UDFM, a 45-year-old female patient with atypical angina had a 14% PTP of obstructive CAD, whereas a male patient with same characteristics had a 38% PTP. It is worth noting that an 85-year-old female patient, who is the oldest patient in the present study with typical angina had a 76% PTP by UDFM. As a result, no woman had a PTP of more than 85% and was classified into the high PTP group. The reclassification table for women (Table [3](#T3){ref-type="table"}) showed that more than half the negative and almost all the positive women were classified into the medium PTP group by UDFM.

Second, the prevalence of CCTA-based obstructive CAD did not correlate well with the presence or type of symptoms [@R25]. The calculation of PTP by traditional models such as UDFM depended on a patient's age, sex, and angina typicality [@R11]. However, especially in women, a previous study had shown that patient symptoms categorized according to the classical definition [@R18] had a limited ability to predict obstructive CAD [@R25],[@R27],[@R28]. This may be account for the unfavorable performance by UDFM in women, whereas DCS that include other risk factors and weakened prediction effect of angina typicality [@R19] improved the calculation accuracy of PTP with a positive NRI and IDI in this study. Similarly, Almeida *et al.* [@R14] and Jensen *et al.* [@R16] suggested that DCS seemed to perform better than UDFM in the prediction of obstructive CAD. It is worth noting that in the present research, DCS improved risk stratification through different mechanism pathways in men and women. DCS showed an NRI of 16.80% in men, which was ascribed to the reclassification of 30.91% (286/1184) of positive men to the higher PTP group, whereas 22.67% (471/2078) of negative women were reclassified into the lower PTP group, resulting in an NRI of 27.20%.

Recently, several large and real-world trials that were completed in symptomatic individuals showed low rates of cardiovascular event and positive noninvasive testing [@R22],[@R27]--[@R29], especially in women [@R6],[@R29]. In conformity with this, according to the reclassification table in our study, UDFM classified more than half of the negative women into the medium PTP group, which was recommended to undergo noninvasive testing [@R7]--[@R9], and the MACE rate of these women was only 2.6%. In particular, noninvasive testing, especially stress testing, showed well-documented significant false-positive rates in women [@R5]. Therefore, calculation of PTP by UDFM would lead to unnecessary testing and confounded approaches to the evaluation and diagnosis of obstructive CAD in women. Conversely, DCS classified most negative women into the low PTP group, resulting in a positive NRI. Moreover, the rate of MACEs in negative women reclassified into the low PTP group was extremely low. Thus, application of DCS instead of UDFM could alter the diagnostic strategy safely and effectively, leading to an evident decrease in unnecessary testing.

To increase the precision of PTP models in women, further studies may benefit from the following three factors. First, development of sex-specific equations is likely to contribute more toward balancing the variation by sex in the decision-making of the diagnostic strategy for CAD [@R30],[@R31]. Second, with the inclusion of some female-specific risk factors, such as estrogen status and gestational diabetes mellitus, the predictive ability of PTP models improved significantly [@R26],[@R32]. Third, novel markers, such as coronary artery calcium scores [@R13], which are manifestations of subclinical atherosclerosis, have shown the potential to improve the precision of PTP models. From a pathophysiological point of view, compared with risk factors, atherosclerosis per se is more reliable [@R33]. Recently, using CCS, an extended model developed by Genders *et al.* [@R17], improved the prediction compared with the clinical model (cross-validated *c* statistic improvement from 0.79 to 0.88, NRI 102%). Furthermore, an analysis involving data from the PROMISE study showed that addition of CCS improved differentiation and calibration of traditional PTP models in women [@R34].

The present study has limitations that warrant acknowledgement. First, this was a retrospective and single-center analysis. We focused on the initial presentation and evaluation for patients with symptoms suggestive of stable CAD, but those patients who were referred to other tests were excluded, resulting in a marked selection bias. Thus, further multicenter and prospective studies are needed. Second, although the scan was performed by an experienced technician and the image was evaluated by three physicians by consensus, CCTA may overestimate the possibility of obstructive CAD because of the excellent negative predictive value and the moderate positive predictive value compared with invasive coronary angiogram [@R35]. Third, the conclusions of this study should be validated and confirmed in comparative cost-effectiveness analyses with long-term outcome data. Fourth, a new model, the PROMISE minimal-risk tool, was developed recently to identify patients with stable chest pain at very low risk of CAD and clinical events [@R36]. This risk score provided a novel strategy to identify patients in whom noninvasive testing might be deferred safely and outperformed existing PTP models [@R37]. Thus, more external validation investigations are needed in the future to determine whether the application of the PROMISE minimal-risk tool can reduce unnecessary testing safely and effectively, especially for women.

Conclusion
----------

The clinical presentation and calculation of PTP differed significantly by sex in patients presenting with stable chest pain and referred to CCTA. Although the performance of neither model was satisfactory, DCS yielded a more accurate calculation of PTP than UDFM and application of DCS instead of UDFM would result in a significant decrease in inappropriate testing in women. These data suggest that continued investigations in this area are warranted to balance the sex-specific differences in the calculation of PTP.
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